Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 10 | SFE2005 | Next issue

196th Meeting of the Society for Endocrinology and Society for Endocrinology joint Endocrinology and Diabetes Day

Oral Communications

Thyroid and pituitary

ea0010oc9 | Thyroid and pituitary | SFE2005

Association of the thyrotrophin receptor gene (TSHR) with Graves’ disease: evidence from independent UK population based case control and family studies

Brand O , Heward J , Brix T , Carr-Smith J , Connell J , Hegedus L , Hunt P , Robinson B , Wass J , Wiersinga W , Franklyn J , Weetman|S##Gough A

Genetic variants consistently associated with the development of Graves’ disease (GD) have, to date, been general autoimmunity loci including those within the HLA region, the CTLA-4 gene and most recently the PTPN22 gene encoding lymphoid tyrosine phosphatase (LYP). The thyrotophin receptor gene (TSHR) has recently however, been identified as the first Graves’ disease specific susceptibility locus. To further refine association with disease and exclude populat...

ea0010oc10 | Thyroid and pituitary | SFE2005

Treatment of subclinical hypothyroidism with L-thyroxine improves endothelial function due to increase in free T4 levels

Razvi S , Oates|J##Weaver C

Background: Subclinical hypothyroidism (SCH) has been reported as a potent risk factor for cardiovascular disease, independent of cholesterol levels. Endothelial dysfunction, which is the earliest manifestation of atherosclerosis, may account for some of this cardiovascular risk. It has never been studied in a randomised controlled manner whether L-thyroxine therapy improves endothelial function.Methods: 100 patients with SCH (mean TSH of 6.6 mIU/L and n...

ea0010oc11 | Thyroid and pituitary | SFE2005

Mortality and vascular outcomes in the thyroid population: an observational study comparing relative levels of mortality and morbidity using the record linkage of patient level datasets

Flynn R , MacDonald T , Morris A , Jung|G##Leese R

Objective: To describe the mortality and vascular morbidity in patients after treatment for hyperthyroidism and hypothyroidism.Method: We constructed an electronic database using record linkage of a community thyroid follow-up register, radioiodine database, regional biochemistry, regional prescribing database, hospital admissions and regional death certification. This was made possible by a unique patient identifier used locally for all healthcare episo...

ea0010oc12 | Thyroid and pituitary | SFE2005

High frequency of abnormal GH suppression and subclinical acromegaly in a series of patients with thyrotropin-secreting pituitary adenoma

Pramodh S , #Gilbert|# , #Hepburn|# , #Chambers|# , #Al-Sarraj|# , #Mcgregor|# , #Aylwin|#

Background: Thyrotropin-secreting pituitary adenomas (TSH-omas) account for 1% of pituitary tumours. In addition to TSH, these tumours frequently secrete glycoprotein α-subunit (αSU) and up to 50% are immunoreactive for growth hormone (GH), although GH suppression following oral glucose tolerance testing (OGTT) has not been routinely performed in all patients to identify subclinical GH hypersecretion or abnormal GH suppression.Objectives: To ex...

ea0010oc13 | Thyroid and pituitary | SFE2005

Effect of dopamine agonists on prolactinomas and normal pituitary, assessed by dynamic contrast enhanced magnetic resonance imaging

Manuchehri A , #Lowry|# , #Turnbull|# , #Rowland-Hill|# , #Atkin|#

Background: Dopamine agonists may act on prolactinoma size and secretion through additional effects on adenoma vascularity which can be visualised using Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI). To investigate this 23 subjects, 5 with macroprolactinomas (prolactin (PRL) range 14631-500000mU/L), 11 with microprolactinomas (PRL range 621-4777mU/L), 7 individuals with non-lesion hyperprolactinemia and 15 normal volunteers, including 5 females on oral contrac...

ea0010oc14 | Thyroid and pituitary | SFE2005

Comparison of random growth hormone and mean growth hormone on oral glucose in patients with acromegaly

Jayasena C , #Wujanto|# , #Todd|# , Meeran K

Background: Measurement of mean serum growth hormone (GH) during an oral glucose tolerance test (OGTT) is currently used for determination of disease activity in patients with acromegaly post-treatment. In contrast to normal subjects, GH secretion in acromegalic patients is largely non-pulsatile, even after treatment.Aim: To determine if random serum GH correlated with mean serum GH during OGTT in patients with acromegaly post-treatment. Furthermore, we ...

ea0010oc15 | Thyroid and pituitary | SFE2005

Prolactin secretion in the female annexin 1 knockout mouse: effects of ovariectomy and oestrogen replacement

Cover P , #McCulley|# , Buckingham J

The secretion of prolactin is sexually dimorphic and sensitive to changes in gonadal steroid and glucocorticoid status. Reports that the regulatory effects of glucocorticoids on prolactin release are mediated in part via annexin I (ANXA1, 1), have led us to compare prolactin secretion in ANXA1 knockout (KO) and wildtype (WT) mice and to determine the effects ovariectomy and oestrogen replacement (80 nanograms/0.1 ml, s.c./day) on (a) the plasma prolactin concentration (radioim...

ea0010oc16 | Thyroid and pituitary | SFE2005

Expression and function of NR5A1, NR5A2 and NR0B1 in mediating gonadotrophin-releasing hormone (GNRH) function in gonadotroph cell lines

Mirczuk S , Poulet B , Chand A , Burrin|R##Fowkes J

The nuclear receptors, NR5A1 (SF-1), NR5A2 (LRH-1) and NR0B1 (DAX-1), are key regulators of gene expression and development in endocrine tissues. NR5A1 regulates endocrine development and function, and is an important regulator of gene expression in pituitary gonadotrophs. In contrast, little is known regarding the role of NR5A2 in pituitary function. Using a range of anterior pituitary-derived cell lines and primary rat pituitaries, we have investigated the expression and act...